300 North Capital’s Biogen BIIB Stock Holding History

300 North Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-8,500	Closed	-$2.05M	–	109
2013 Q3	$2.05M	Sell	8,500 -1,100	-11%	-$246K	0.48%	86
2013 Q2	$2.07M	Buy	+9,600	New	+$2.05M	0.8%	55

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

300 North Capital's BIIB Position: Q4 2013 in Review

300 North Capital sold out of Biogen (BIIB) in Q4 2013, closing a stake of 8,500 shares — an estimated $2.05M sold.

300 North Capital first reported a position in BIIB in Q2 2013 and held it in 2 quarters. The position peaked at $2.07M in Q2 2013. 738 funds tracked by Wall St. Rank hold BIIB as of Q4 2013.

300 North Capital reported no remaining Biogen position as of Q4 2013 after selling out during the quarter.
300 North Capital sold 8,500 Biogen shares in Q4 2013, an estimated $2.05M.
300 North Capital first reported a position in Biogen in Q2 2013 and held it in 2 quarters.
300 North Capital's Biogen position peaked at $2.07M in Q2 2013.
738 funds tracked by Wall St. Rank held Biogen as of Q4 2013.

Based on 300 North Capital's 13F filing for Q4 2013, filed 14 Feb 2014.